Call for Speaker Proposals
제3회
Cancer Biologics
-항암생물제제 학회-
복합체, 다중특이성, 바이오마커 및 최신 접근법
2월 21일∼23일
3년째를 맞이하는 이 학회는 Oncology drug discovery에 관련된 중요 분야 및 새로운 분야에 대해 배울 수 있는 귀중한 기회이며, 강력한 표적 설정 기능 및 이펙터 기능을 실현하는 최신 공학적 접근법에서 임상전 개발과 중개연구, 임상적인 진전과 같은 테마가 다루어집니다. 또한 항체 약물 복합체, 다중특이성 제품, 병용요법, 면역치료, 백신 등에도 초점을 맞추며, 핵산생물제제 및 암줄기세포의 표적화라는 새로운 분야에 대한 최신 접근법, 전달과 종양 침투에 관 련된 과제를 극복하는 수단 등도 검토할 예정입니다.
Who should attend: VPs, Directors, CEOs, CSOs and Scientists from Large Pharma, Biotechs and Academia in such fields as R&D, Product Development, Translational Medicine, Protein Engineering, Target Discovery
Topics will include, but are not limited to advances in the following:
- Advances with antibody-drug conjugates
- Bi- and multi-specific biotherapeutics
- Combination therapies
- Nucleic acid therapies (RNAi and siRNA)
- Immunotherapies, vaccines and adoptive T cell therapy
- Targeting cancer stem cells
- Identification of novel targets
- Novel engineering and platforms
- Penetration and delivery to solid tumors
- Translational and clinical biomarkers
- Pre-clinical and clinical advances
- Strategies for regulatory approval, licensing and success in the market
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
